Atorvastatin inhibits angiotensin-converting enzyme induction in differentiating human macrophages

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 292, Issue 4, 2007, Pages

  Saijonmaa, Outi ^a,b   Nyman, Tuulikki ^a   Fyhrquist, Frej ^a,b  

^a MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Cell culture; Mevalonate; Peripheral blood monocytes; Statin

Indexed keywords

ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MEVALONIC ACID;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; MACROPHAGE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CELL DIFFERENTIATION; ENZYME INDUCTION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACROPHAGES; MEVALONIC ACID; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PHOSPHORYLATION; POLYISOPRENYL PHOSPHATES; PROTEIN KINASE C; PYRROLES; RNA, MESSENGER; SESQUITERPENES; TERPENES; UP-REGULATION;

EID: 34147125246     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00920.2006     Document Type: Article

References (21)

1. Cilla D, Whitfield L, Gibson D, Sedman A, Posvar E. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 60: 687-695, 1996.
2. Dzau V, Bernstein K, Celermajer D, Cohen J, Dahlöf B, Deanfield J, Diez J, Drexler H, Ferrari R, van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, Lonn E, Lüscher T, Mancini J, Mimran A, Pepine C, Rabelink T, Remme W, Ruilope L, Ruzicka M, Schunkert H, Swedberg K, Unger T, Vaughan D, Weber M. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 88, Suppl: 1L-20L, 2001.
3. Fukuhara M, Geary R, Diz D, Gallagher P, Wilson J, Glazier S, Dean R, Ferrario C. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 35: 353-359, 2000.
4. Fyhrquist F, Tikkanen I, Grönhagen-Riska C, Hortling L, Hichens M. Inhibitor binding assay for angiotensin converting enzyme. Clin Chem 30: 696-700, 1984.
5. Hayek T, Pavlotzky E, Homoud S, Coleman R, Keidar S, Aviram M, Kaplan M. Tissue angiotensin-converting-enzyme (ACE) deficiency leads to a reduction in oxidative stress and in atherosclerosis. Studies in ACE-knockout mice type 2. Arterioscler Thromb Vasc Biol 23: 2090-2096, 2003.
6. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl- CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101: 2711-2719, 1998.
7. Ichiki T, Takeda K, Tokunou T, Iino N, Egashira K, Shimokawa H, Hirano K, Kanaide H, Takeshita A. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21: 1896-1901, 2001.
8. Jackson B, Cubela R, Johnston C. Characterization of angiotensin converting enzyme from rat tissue by radio-inhibitor binding studies. Clin Exp Pharmacol Physiol 13: 681-689, 1986.
9. Junttila I, Bourette R, Rohrschneider L, Silvennoinen O. M-CSF induced differentiation of myeloid precursor cells involves activation of PKC-δ and expression of Pkare. J Leukoc Biol 73: 281-288, 2003.
10. Laufs U, La Fata V, Pluzky J, Liao J. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129-1135, 1998.
11. Negre-Aminou P, van Vliet A, van Erck M, van Thiel G, van Leeuwen R, Cohen L. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: comparison with other human cell types. Biochim Biophys Acta 1345: 259-268, 1997.
12. Saijonmaa O, Fyhrquist F. Upregulation of angiotensin converting enzyme by atrial natriuretic peptide and cyclic GMP in human endothelial cells. Cardiovasc Res 40: 206-210, 1998.
13. Saijonmaa O, Nyman T, Kosonen R, Fyhrquist F. Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. Am J Physiol Heart Circ Physiol 280: H885-H891, 2001.
14. Saijonmaa O, Nyman T, Stewen P, Fyhrquist F. Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells. Am J Physiol Heart Circ Physiol 286: H2096-H2102, 2004.
15. Takemoto M, Liao J. Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719, 2001.
16. Teupser D, Bruegel M, Stein O, Stein Y, Thiery J. HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells. Biochem Biophys Res Commun 289: 838-844, 2001.
17. Vamvakopoulos J, Green C. HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statin-mediated vasculoprotection. BMC Cardiovasc Disord 3: 6, 2003.
18. Villard E, Alonso A, Agrapart M, Challah M, Soubrier F. Induction of angiotensin I-converting enzyme transcription by a protein kinase C-dependent mechanism in human endothelial cells. J Biol Chem 273: 25191-25197, 1998.
19. Vincent L, Soria C, Mirshahi F, Opolon P, Mishal Z, Vannier JP, Soria J, Hong L. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in vivo models. Arterioscler Thromb Vasc Biol 22: 623-629, 2002.
20. Watanabe K, Lam G, Keresztes R, Jaffe E. Lipopolysaccharides decrease angiotensin converting enzyme activity expressed by cultured human endothelial cells. J Cell Physiol 150: 433-439, 1992.
21. Weiss D, Sorescu D, Taylor R. Angiotensin II and atherosclerosis. Am J Cardiol 87, Suppl: 25C-32C, 2001.